Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Synergy CHC Corp. operates in the healthcare distribution sector, focusing on consumer health products across North America and Europe. The company leverages its extensive distribution network and partnerships with leading manufacturers to deliver a diverse range of over-the-counter medications and wellness products.
Synergy CHC Corp. generates revenue primarily through the distribution of consumer health products to pharmacies and retailers. The company benefits from strong relationships with manufacturers, allowing for competitive pricing and exclusive product offerings. Its high gross margin of 66.8% indicates effective cost management and pricing power in its niche.
Changes in consumer health product demand, particularly seasonal fluctuations in over-the-counter medications
Regulatory changes affecting product approvals and distribution practices
Partnership announcements with major retailers or manufacturers
Market share shifts in the competitive landscape
Regulatory changes that could impact product distribution and compliance costs
Technological disruption in the distribution and retail landscape
Increased competition from larger distributors with more extensive networks
Emergence of private label products that could undercut pricing
Negative operating cash flow indicating potential liquidity issues
High ROE of 91.3% may mask underlying operational inefficiencies
moderate - The company is somewhat sensitive to economic cycles, as consumer health spending can decline during economic downturns.
Interest rates affect the company's financing costs and consumer spending power, with higher rates potentially dampening demand for discretionary health products.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on external financing.
value - Investors may be attracted by the low price/sales ratio of 0.1x, indicating potential undervaluation.
high - The stock has experienced significant volatility, with a 1-year return of -94.8%.